Clinical Trial Update: Respreeza® Self-administration and Learning Program (AmAREtTI Study)

View source ↗

Summary

The AmAREtTI study evaluating Respreeza self-administration and a learning program for Alpha-1 Antitrypsin Deficiency has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Respreeza (alpha-1 proteinase inhibitor (human))

Snippet

Sponsor: CSL Behring | Conditions: Alpha-1 Antitrypsin Deficiency | Status: COMPLETED